Idebenone: A Review in Leber's Hereditary Optic Neuropathy

Area of Science:

• Biochemistry
• Genetics
• Ophthalmology

Background:

• Leber's hereditary optic neuropathy (LHON) is a rare genetic mitochondrial disease causing rapid, progressive bilateral vision loss.
• Visual impairment in LHON affects adolescents and adults, necessitating disease-specific treatments.

Purpose of the Study:

• To evaluate the efficacy of idebenone in treating visual impairment associated with Leber's hereditary optic neuropathy (LHON).
• To assess the long-term benefits of idebenone in preventing vision loss and promoting recovery in LHON patients.

Main Methods:

• The study analyzed data from a randomized clinical trial, a follow-up study, and real-world evidence.
• Patients received oral idebenone 900 mg/day for 24 weeks.

Main Results:

• Idebenone demonstrated persistent beneficial effects in preventing further vision impairment.
• The treatment promoted vision recovery in patients with LHON compared to the disease's natural progression.
• Idebenone functions as an antioxidant and mitochondrial electron carrier, bypassing complex I deficiency to restore ATP production and reactivate retinal ganglion cells.

Conclusions:

• Idebenone is an effective and valuable therapeutic agent for visual impairment in adolescents and adults with LHON.
• The drug's mechanism involves restoring cellular energy and protecting retinal cells, leading to improved visual outcomes.